Results 81 to 90 of about 37,371 (257)

Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. [PDF]

, 2017
BACKGROUND: Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran. METHODS: We performed a multicenter, prospective, open-label study to determine whether 5 g of intravenous idarucizumab would be ...
Bernstein, Richard A., Dubiel, Robert, Eikelboom, John W., Glund, Stephan, Huisman, Menno V., Hylek, Elaine M., Kam, Chak-Wah, Kamphuisen, Pieter W., Kreuzer, Jörg, Levy, Jerrold H., Pollack, Charles V., Reilly, Paul A., Royle, Gordon, Sellke, Frank W., Stangier, Joachim, Steiner, Thorsten, van Ryn, Joanne, Verhamme, Peter, Wang, Bushi, Weitz, Jeffrey I., Young, Laura   +20 more
core   +1 more source

Is there a role for oral triple therapy in patients with acute coronary syndromes without atrial fibrillation? [PDF]

, 2018
© 2018 Bentham Science PublishersBACKGROUND: Acute coronary syndrome (ACS) patients, despite treatment with dual antiplatelet therapy (DAPT), have up to 10% risk of recurrent major adverse cardiac events (MACE) in the short term.
Akhtar, Zaki, Farag, Mohamed, Gorog, Diana Adrienne, Spinthakis, Nikolaos   +3 more
core   +2 more sources

Adjustment for ‘Prescriber Type’ in Pharmacoepidemiological Analyses

Basic &Clinical Pharmacology &Toxicology, Volume 137, Issue 5, November 2025.
ABSTRACT The type of prescriber typically fulfils the criteria for confounding, as it is associated both with the exposure (e.g., prescriber types may differ in their choice of first‐line treatment) and with the outcome (as different types of prescribers often treat patients with different disease severity).
Saad Hanif Abbasi, Jesper Hallas, Peter Bjødstrup Jensen, Hassan Al‐Jasim, Anton Pottegård   +4 more
wiley   +1 more source

The clinical effectiveness and cost-effectiveness of point-of-care tests (CoaguChek system, INRatio2 PT/INR monitor and ProTime Microcoagulation system) for the self-monitoring of the coagulation status of people receiving long-term vitamin K antagonist therapy, compared with standard UK practice : systematic review and economic evaluation [PDF]

, 2015
Funding The National Institute for Health Research Health Technology Assessment programme.Peer reviewedPublisher ...
, , , , , , , , , , , , , , , , , , , , Ahmad, Ansell, Ascione, Azarnoush, Bauman, Bauman, Bauman, Bayer, Bereznicki, Bloomfield, Braun, Briggs, Bronnum-Hansen, Brown, Cayley, Christensen, Christensen, Christensen, Christensen, Christensen, Christensen, Connock, Connolly, Cromheecke, Curtis, Dauphin, DeWilde, Dorman, Drummond, Dunning, Edwards, Eitz, Fitzmaurice, Fitzmaurice, Fitzmaurice, Friberg, Friberg, Fuster, Gadisseur, Gadisseur, Gailly, Gallagher, Garcia-Alamino, Gardiner, Gardiner, Go, Hallan, Havrda, Hemkens, Heneghan, Heneghan, Hentrich, Higgins, Hobbs, Horstkotte, Horstkotte, Horstkotte, Hylek, Jackson, Jones, Jones, Jowett, Kannel, Khan, Kind, Kitchen, Koertke, Koertke, Koertke, Kvidal, Körtke, Körtke, Lafata, Lee, Marini, Matchar, Matchar, Matchar, McCahon, Menéndez-Jándula, Moher, Moon, Muller, Murray, Paioni, Pollack, Rasmussen, Regier, Robinson, Rose, Ruel, Ryan, Ryan, Ryan, Saka, Sawicki, Sawicki, Schmidt, Sidhu, Siebenhofer, Siebenhofer, Slot, Sobieraj-Teague, Sola-Morales, Soliman Hamad, Spackman, Sudlow, Sullivan, Sundberg, Sunderji, Sunderji, Taborski, Tamayo, Vahanian, van, Verret, Visnansky, Voller, Völler, Wallentin, Wallentin, Wang, Wardlaw, Wells, Williams, You   +145 more
core   +1 more source

Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation

Patient Preference and Adherence, 2014
Jiyoon C Choi,1 Marco d DiBonaventura,2 Lewis Kopenhafer,2 Winnie W Nelson31LifeScan, Inc, West Chester, PA, 2Health Sciences Practice, Kantar Health, New York, NY, 3Janssen Scientific Affairs LLC, Raritan, NJ, USABackground: Oral dabigatran was recently
Choi JC, DiBonaventura Md, Kopenhafer L, Nelson WW   +3 more
doaj  

Clinical associations and prognosis in Asian and European patients with symptom‐controlled atrial fibrillation: Insights from two prospective registries in Europe and Asia

European Journal of Clinical Investigation, Volume 55, Issue 11, November 2025.
Symptom‐controlled atrial fibrillation (AF), defined as asymptomatic or with mild symptoms according to the European Heart Rhythm Association (EHRA) score, was more common among Asians than in Europeans. In Asians, comorbidities of diabetes, hypertension, and prior ischemic stroke increase the likelihood of being scAF.
Wee Siong Teo, Manlin Zhao, Tommaso Bucci, Steven Ho Man Lam, Hongyu Liu, Yang Chen, Giuseppe Boriani, Hung‐Fat Tse, Tze‐Fan Chao, Gregory Y. H. Lip   +9 more
wiley   +1 more source

Medication Utilization Evaluation of Dabigatran and Rivaroxaban within a Large, Multicenter Health System. [PDF]

, 2013
Objective. The objective of this medication utilization evaluation (MUE) was to determine the appropriateness of dabigatran and rivaroxaban while also reviewing outcomes for safety and effectiveness within a large, multi-center health system. Methods.
Doolin, Meagan, Issacs, Alex N., Morse, Courtney, Nisly, Sarah A., Shiltz, Erin   +4 more
core   +1 more source

Coagulation and anticoagulation in idiopathic pulmonary fibrosis [PDF]

, 2015
Idiopathic pulmonary fibrosis (IPF) is an incurable, progressive interstitial lung disease with a prognosis that is worse than that of many cancers. Epidemiological studies have demonstrated a link between IPF and thrombotic vascular events.
Crooks, Michael G., Hart, Simon P.
core   +3 more sources

Oral anticoagulation in patients with gastrointestinal bleeding and new‐onset atrial fibrillation: A population‐based registry‐linkage study

Journal of Internal Medicine, Volume 298, Issue 5, Page 450-463, November 2025.
Abstract Background Limited data exist on the prevalence of gastrointestinal bleeding (GIB) in patients with new‐onset atrial fibrillation (AF) and the impact of GIB on the initiation of oral anticoagulation (OAC) therapy. Methods A population‐based registry‐linkage study included all patients diagnosed with new‐onset AF in Finland during 2010–2018 who
Santeri Jolkkonen, Jukka Putaala, Konsta Teppo, Pirjo Mustonen, Jussi Jaakkola, Aapo Aro, Olli Halminen, Ossi Lehtonen, Jari Haukka, Miika Linna, Juha Hartikainen, K. E. Juhani Airaksinen, Mika Lehto   +12 more
wiley   +1 more source

Dabigatran experience in primary and secondary prevention of cardioembolic stroke

Неврология, нейропсихиатрия, психосоматика, 2013
The review of novel oral anticoagulants (dabigatran, rivaroxaban and apixaban) in stroke prevention and also own data of administration of dabigatran in primary and secondary prevention of ischemic stroke in 45 patients with cerebrovascular diseases are ...
Maksim Alekseyevich Domashenko, M Yu Maksimova, D Z Korobkova, M E Gafarova   +3 more
doaj   +1 more source